Can Novan Nitric Oxide Based Approach pay off in the long run?
Novan, Inc. (NASDAQ: NOVN), a clinical–stage Biotechnology Company leveraging its expertise in nitric oxide-based therapies, has entered into a Master Services Agreement (MSA) with Catalent for supporting the development and chemistry, manufacturing and control (CMC) activities for berdazimer sodium, to be made into an intranasal...